<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00288444</url>
  </required_header>
  <id_info>
    <org_study_id>174-2004</org_study_id>
    <secondary_id>EU841-03</secondary_id>
    <nct_id>NCT00288444</nct_id>
  </id_info>
  <brief_title>Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer</brief_title>
  <official_title>Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <brief_summary>
    <textblock>
      To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To determine the safety and toxicity of intravenous docetaxel, administered on a weekly&#xD;
           schedule (3 weeks out of 4), in combination with oral lonafarnib, administered on a&#xD;
           daily schedule, in patients with locally advanced and metastatic solid tumor&#xD;
           malignancies which are refractory to the standard of care.&#xD;
&#xD;
        2. To determine the pharmacokinetic interaction between docetaxel and lonafarnib.&#xD;
&#xD;
        3. To determine the molecular interaction in peripheral blood mononuclear cells between&#xD;
           docetaxel and lonafarnib&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the molecular interaction</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine safety and efficacy</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 30 mg/ m2and Lonafarnib 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 36 mg/ m2 and Lonafarnib 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 30 mg/m2 and Lonafarnib 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonafarnib</intervention_name>
    <arm_group_label>Docetaxel 30 mg/ m2and Lonafarnib 150 mg</arm_group_label>
    <arm_group_label>Docetaxel 30 mg/m2 and Lonafarnib 100 mg</arm_group_label>
    <arm_group_label>Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg</arm_group_label>
    <arm_group_label>Docetaxel 36 mg/ m2 and Lonafarnib 100 mg</arm_group_label>
    <other_name>SCH66336</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel 30 mg/ m2and Lonafarnib 150 mg</arm_group_label>
    <arm_group_label>Docetaxel 30 mg/m2 and Lonafarnib 100 mg</arm_group_label>
    <arm_group_label>Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg</arm_group_label>
    <arm_group_label>Docetaxel 36 mg/ m2 and Lonafarnib 100 mg</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:.1.1 Patient must have a pathologically-confirmed locally advanced or&#xD;
        metastatic solid tumor malignancy demonstrated to be refractory to the standard of care,&#xD;
        with tumors accessible by needle or surgical biopsy.&#xD;
&#xD;
        3.1.2 Only patients determined to be at minimal risk to receiving the biopsy (with tumor&#xD;
        location/accessibility as well as underlying patient comorbidities judged to allow a&#xD;
        minimal risk biopsy by the radiologist/surgeon performing the procedure) will be eligible&#xD;
        for this study.&#xD;
&#xD;
        3.1.3 Patient must have an ECOG performance status of 2 or less.&#xD;
&#xD;
        3.1.4 Patient must have a life-expectancy of at least 12 weeks.&#xD;
&#xD;
        3.1.5 Patient must have adequate bone marrow function: WBC ≥ 3,000 cells/mm3, ANC ≥ 1,500&#xD;
        cells/mm3, platelet count ≥ 100,000/mm3 and Hgb ≥ 9.0 g/dL.&#xD;
&#xD;
        3.1.6 Patient must have adequate liver function: total bilirubin level ≤ 2.0 mg/dL and ≤&#xD;
        ULN, albumin ≥ 2.5 g/dL.&#xD;
&#xD;
        3.1.7 Patient must have adequate renal function: Transaminases/Alkaline phosphatase: AST or&#xD;
        ALT and alkaline phosphatase must be within the range allowing for eligibility. This range&#xD;
        is defined as ≤ 2 x ULN.&#xD;
&#xD;
        In determining eligibility, the more abnormal of the two (AST or ALT) should be used.&#xD;
&#xD;
        3.1.8 Patient must have received no more than three previous chemotherapy regimens (prior&#xD;
        chemotherapy may or may not have contained a taxane).&#xD;
&#xD;
        3.1.9 Patient must meet the specified informed consent requirement.&#xD;
&#xD;
        3.1.10 Patient must be of age ≥ 18 years.&#xD;
&#xD;
        3.1.11 Women of childbearing age must have a negative pregnancy test.&#xD;
&#xD;
        3.1.12 Men and women of childbearing potential must be willing to consent to using&#xD;
        effective contraception while on treatment and for at least 3 months thereafter.&#xD;
&#xD;
        3.1.13 Patient must have ≤ Grade 1 neurotoxicity from previous anticancer treatment or from&#xD;
        any cause.&#xD;
&#xD;
        3.1.14 Patient must have adequate coagulation function: INR and PTT ≤ 1.5 x ULN.&#xD;
&#xD;
        3.1.15 Patient must have discontinued all prior chemotherapy and radiotherapy at least 4&#xD;
        weeks prior to registration.&#xD;
&#xD;
        3.1.16 Patient must have discontinued use of the following drugs which are an inducers or&#xD;
        inhibitors of CYP3A4 at least 2 days prior to registration: ethinylestradiol, gestodene,&#xD;
        itraconazole, ketoconazole, cimetidine, erythromycin, carbamazepine, high dose chronic&#xD;
        steroids, phenobarbital, phenytoin, rifampin (rifampcin), and sulfinpyrazone.&#xD;
&#xD;
        Patient must have a pathologically-confirmed&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        3.2.1 Patient has received more than three previous chemotherapy regimens.&#xD;
&#xD;
        3.2.2 Patient is pregnant or breast feeding.&#xD;
&#xD;
        3.2.3 Patient has signs of symptoms of acute infection requiring systemic therapy.&#xD;
&#xD;
        3.2.4 Patient exhibits confusion, disorientation, or has a history of major psychiatric&#xD;
        illness which may impair the patient's understanding of the informed consent.&#xD;
&#xD;
        3.2.5 Patient's life expectancy is less than 12 weeks.&#xD;
&#xD;
        3.2.6 Patient has &gt; Grade 1 neurotoxicity from previous anticancer treatment or significant&#xD;
        neuropathy from any cause.&#xD;
&#xD;
        3.2.7 Patient requires total parenteral nutrition with lipids.&#xD;
&#xD;
        3.2.8 Inability to swallow the lonafarnib BID.&#xD;
&#xD;
        3.2.9 Patient has a history of uncontrolled heart disease (including clinically significant&#xD;
        coronary artery disease, congestive heart failure and symptomatic or uncontrolled&#xD;
        arrythmias).&#xD;
&#xD;
        3.2.10 Patient has a history of severe hypersensitivity reaction to docetaxel or other&#xD;
        drugs formulated with polysorbate 80. Symptoms include: any reaction such as bronchospasm,&#xD;
        generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema.&#xD;
&#xD;
        3.2.11 Use of chronic steroids or anticonvulsants.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kauh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2006</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>John Kauh</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Advanced malignancies.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

